Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Evolution of molecular targets in melanoma treatment

(2020) Khanh Bao Tran et al.   CURRENT PHARMACEUTICAL DESIGN

Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma

(2020) Khanh B. Tran et al.   Pigment Cell & Melanoma Research

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients

(2020) Franz J. Hilke et al.   Cancers

Identification and characterization of two novel oncogenic mTOR mutations

(2019) Avaniyapuram Kannan Murugan et al.   ONCOGENE

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

(2019) Jonathan A. Trujillo et al.   Journal for ImmunoTherapy of Cancer

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

(2018) Gabriele Romano et al.   Cancer Discovery

Melanoma

(2018) Dirk Schadendorf et al.   LANCET

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

(2018) Sunilkumar Kakadia et al.   OncoTargets and Therapy

PIK3CA -mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation

(2017) Jillian M. Silva et al.   Pigment Cell & Melanoma Research

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor

(2016) Hélène Bonnevaux et al.   MOLECULAR CANCER THERAPEUTICS

The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis

(2015) Lisa M. Ooms et al.   CANCER CELL

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors

(2015) Y. Kong et al.   CLINICAL CANCER RESEARCH

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

(2015) Melanie Sweetlove et al.   Frontiers in Oncology

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma

(2014) Marian M. Deuker et al.   Cancer Discovery

Phosphoinositide 3-kinase and INPP4B in human breast cancer

(2013) Micka C. Bertucci et al.   Annals of the New York Academy of Sciences

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma

(2013) L. N. Kwong et al.   CLINICAL CANCER RESEARCH

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma

(2013) Victoria Marsh Durban et al.   JOURNAL OF CLINICAL INVESTIGATION

A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms

(2013) Rolando Perez-Lorenzo et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation

(2012) Niki Tzenaki et al.   FASEB JOURNAL

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma

(2012) Austin Y. Shull et al.   PLoS One

Elucidating Distinct Roles for NF1 in Melanomagenesis

(2012) Ophélia Maertens et al.   Cancer Discovery

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

(2011) Stephen Jamieson et al.   BIOCHEMICAL JOURNAL

Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolismin vivo

(2011) Greg C. Smith et al.   BIOCHEMICAL JOURNAL

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Genetic alterations of PTEN in human melanoma

(2011) Almass-Houd Aguissa-Touré et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase (PHLPP): A New Player in Cell Signaling

(2011) Noel A. Warfel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells

(2010) Y. Shao et al.   CANCER RESEARCH

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

(2010) C. G. Fedele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer-derived mutations in the regulatory subunit p85  of phosphoinositide 3-kinase function through the catalytic subunit p110 

(2010) M. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

(2009) R. Marone et al.   MOLECULAR CANCER RESEARCH

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA